MNOV insider filings
MEDICINOVA INC — 25 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-09-29. Screen MNOV transaction legs live →
Insider transaction summary — last 90 days
2026-07-10 to 2026-10-08, from the filings listed below: 1 insider filing (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 1 leg across 1 filing by 2 insiders — 640,000 shares, $1,728,000 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 0.
- Largest priced transaction: sale of 640,000 shares @ $2.70 ($1,728,000) by 3D Investment Partners Pte. Ltd., filed 2026-09-29.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| 3D Investment Partners Pte. Ltd. & 3D Opportunity Master Fund | 1 | — | 1 leg · 640,000 sh · $1,728,000 | — |
Recent insider filings — MEDICINOVA INC
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-29 | 4 | 3D Investment Partners Pte. Ltd. 3D Opportunity Master Fund | Sale (S): 640,000 @ $2.70 | EDGAR |
| 2026-06-25 | 4 | Nagao Hideki — Director | Grant/award (A): 44,500 (derivative) @ $0 | EDGAR |
| 2026-06-25 | 4 | Lemerond Nicole — Director | Grant/award (A): 44,500 (derivative) @ $0 | EDGAR |
| 2026-06-25 | 4 | BEAVER CAROLYN — Director | Grant/award (A): 44,500 (derivative) @ $0 | EDGAR |
| 2026-01-20 | 4 | Matsuda Kazuko — Chief Medical Officer | Grant/award (A): 350,000 (derivative) @ $0 | EDGAR |
| 2026-01-20 | 4 | IWAKI YUICHI — President and CEO | Grant/award (A): 450,000 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Lemerond Nicole — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Nagao Hideki — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | BEAVER CAROLYN — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-02-14 | 4 | Nagao Hideki — Director | Grant/award (A): 24,500 (derivative) @ $0 | EDGAR |
| 2025-02-14 | 4 | Matsuda Kazuko — Chief Medical Officer, Director | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2025-02-14 | 4 | Lemerond Nicole — Director | Grant/award (A): 24,500 (derivative) @ $0 | EDGAR |
| 2025-02-14 | 4 | IWAKI YUICHI — President and CEO, Director | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2025-02-14 | 4 | BEAVER CAROLYN — Director | Grant/award (A): 24,500 (derivative) @ $0 | EDGAR |
| 2025-01-10 | 4 | Matsuda Kazuko — Chief Medical Officer, Director | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2025-01-10 | 4 | IWAKI YUICHI — President and CEO, Director | Grant/award (A): 400,000 (derivative) @ $0 | EDGAR |
| 2024-06-12 | 4 | Nagao Hideki — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2024-06-12 | 4 | Lemerond Nicole — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2024-06-12 | 4 | BEAVER CAROLYN — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2024-01-11 | 4 | OBrien Geoffrey — Vice President | Grant/award (A): 84,000 (derivative) @ $0 | EDGAR |
| 2024-01-11 | 4 | Matsuda Kazuko — Chief Medical Officer, Director | Grant/award (A): 157,500 (derivative) @ $0 | EDGAR |
| 2024-01-11 | 4 | IWAKI YUICHI — President and CEO, Director | Grant/award (A): 210,000 (derivative) @ $0 | EDGAR |
| 2023-08-08 | 4 | Lemerond Nicole — Director | Grant/award (A): 18,333 (derivative) @ $0 | EDGAR |
| 2023-06-15 | 4 | Nagao Hideki — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2023-06-15 | 4 | BEAVER CAROLYN — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — MEDICINOVA INC
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-28 | 8-K | 1.01 — Entry into a Material Definitive Agreement | EDGAR |
| 2026-09-02 | 8-K | 1.02 — Termination of a Material Definitive Agreement | EDGAR |
| 2026-08-19 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-06-24 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-02-20 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-30 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-01 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-06-18 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2025-03-11 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-06-12 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=MNOV returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →